

Rate, Risk Factors, and Outcomes of Invasive Fungal Infections in Patients with Hematologic Malignancies

Shirin Afhami¹, Alireza Adibimehr², Seyed Asadollah Mousavi^{3,4}, Mohammad Vaezi^{4,5}, Mahnaz Montazeri⁶, Mohammadreza Salehi⁷, Mohsen Meidani⁷, Mahshid Saleh⁸, Kazem Ahmadikia⁹, Emmanuel Roilides¹⁰, Johan Maertens^{11,12}, Neda Alijani¹

¹Department of Infectious Diseases, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

²Department of Infectious Diseases, Kamkar Arbna Hospital, Qom University of Medical Sciences (QUMS), Qom, Iran

³Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran

⁴Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran

⁵Hematology, Oncology and Stem cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran

⁶Department of Infectious Diseases, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran

⁷Department of Infectious Diseases, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

⁸Wisconsin National Primate Research Center, University of Wisconsin Graduate School, Madison, Wisconsin, USA

⁹Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

¹⁰Infectious Diseases Unit, 3rd Department of Paediatrics, Aristotle University School of Medicine, Hippokraton General Hospital, Thessaloniki, Greece

¹¹Department of Microbiology, Immunology, and Transplantation, K.U. Leuven, Leuven, Belgium

¹²Department of Hematology, U.Z. Leuven, Leuven, Belgium

Corresponding Author: Neda Alijani, Department of Infectious Diseases, Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

E-mail: n-alijani@sina.tums.ac.ir

Received: 24, May, 2022

Accepted: 20, Sep, 2023

ABSTRACT

Background: Invasive fungal infections (IFIs) are a significant cause of mortality and morbidity in patients with hematological malignancies. Given the considerable prevalence and consequences of IFIs, hence revealing the exact cause of fungal infections, their rate, associated risk factors, and complications could contribute to reducing both financial and life costs, choosing targeted antifungal treatment, and avoiding unnecessary toxic treatments in individuals who are not suffering from mycoses.

Materials and Methods: This prospective cross-sectional study was conducted in the first semester of 2019. All patients with hematologic malignancies (HM) admitted to Dr. Shariati Hospital were studied. Only those with probable/proven IFIs defined according to the last update of EORTC/MSG criteria were included in the study. The demographic and clinical data were recorded from the hospital information registration system using a questionnaire. Statistical analysis was performed using SPSS software version 24.

Results: Out of 1109 HM patients hospitalized during the study period, 67 (6.04%) IFIs were diagnosed. Of these, 57 (85.04%) were aspergillosis, 7 (10.4%) were mucormycosis, and 3 patients developed other fungal infections. Males constituted 67.2% of the entire IFI population. The mean±SD age of the samples was 43.16 ± 13.8 years. The most common type of malignancy was AML. Lung imaging showed lesions associated with fungal infections in 52 cases (77.6%), with multiple nodules as the most prevalent pattern being observed in 64.2% of cases. Sinus involvement was evidenced in the PNS CT scan of 46 (68.6%) patients. The attributable mortality rate for IFIs was 62.7%. Both the types of IFI and malignancies had no significant relationship with the outcome of patients. Central venous catheter, mucositis, and antibiotic use were the most frequent risk factors.

Conclusion: IFI represents a frequent complication for HM patients with high mortality. *Aspergillus* species are the predominant etiology in these settings. Considering our results, in high-risk patients, manifestations of warning signs in the sinus and lungs, which would not be cleared despite receiving antibiotics, should raise the possibility of IFIs.

Keywords: Hematologic malignancy; Invasive fungal infection; Aspergillosis; AML; Risk factors

INTRODUCTION

One of the most common problems seen in patients with hematologic malignancies (HMs) is their susceptibility to opportunistic infections, including fungal infections, which have been reported in up to 18.1% of those hospitalized in this setting¹, and invasive fungal infections (IFIs) are important causes of morbidity and mortality in these patients. Chemotherapy and ensuing neutropenia disrupt one of the main arms of innate immune system (e.g. phagocytosis).

Defects in the phagocytic process are leading causes of IFIs in acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), and hairy cell leukemia (HCL). Moreover, lack of T cells as well as T cell and macrophage dysfunction predispose to IFIs in leukemia, T cell lymphoma, and Hodgkin's disease². Among yeasts, *Candida* spp. are considered the most common causes of IFIs. The prevalence of invasive candidiasis (IC) in patients with HM who have not received prophylaxis is reported to be 8-24%. *Candida* species are part of normal flora of skin, mouth, intestines, and vagina. Mucosal damage in patients undergoing chemotherapy and neutropenia can lead to systemic infection by these fungi. In the induction phase of AML chemotherapy, the main risk factor of IC is mucosal and gastrointestinal damage. After *Candida*, the most common yeast causing IFIs is *Cryptococcus* species which is mainly manifested as cryptococcal meningitis^{3,4}. In patients with AML, not receiving mold-active prophylaxis, the prevalence of invasive aspergillosis (IA) is estimated to be between 5-10%. The leading cause of IA is multiple chemotherapies in persistent or progressive AML^{5,6}. Mucormycosis is the second most common cause of invasive mold infections (IMIs) in patients with HMs. Mucormycosis can cause severe infections of the sinuses, lungs, and brain or some disseminate to other parts of the body^{7,8}. In general, the risk of IFIs in patients with acute leukemia and bone marrow transplant recipients is higher than in patients with chronic leukemia, lymphoma, and multiple myeloma. As a result, the rate of morbidity and mortality in patients with acute leukemia and bone marrow transplant recipients is higher compared to chronic leukemia, lymphoma, and multiple myeloma^{9,10}. Candidemia and IA are

associated with poor prognosis and a mortality rate of 33% and 42%, respectively. Mucormycosis has the worst prognosis among IFIs, with a mortality rate of 64%¹¹⁻¹³.

Considering the significant prevalence and consequences of IFIs in patients with HM imposing severe human and financial costs on society, guiding in choosing antifungal prophylaxis regimen and targeted therapy, revealing the rate of IFIs in hematology setting is issue of great importance. Therefore, this study was conducted to assess the risk factors, rate, and consequences of IFIs in patients with HMs.

MATERIALS AND METHODS

This prospective cross-sectional study was conducted in the hematology ward of Dr. Shariati Hospital, a tertiary referral center affiliated to Tehran University of Medical Sciences (TUMS), Tehran, Iran, between April 1, 2019, and September 20, 2019. The study population targeted all adult patients (aged over 16 years) with HM admitted to the hematology wards during the survey period. All documented episodes of IFI were included. Patients with solid organ malignancies, outpatient cases, concomitant HMs, and instances such as HIV, bone marrow transplant recipients, solid organ transplant recipients, patients with underlying rheumatic diseases who received high doses of corticosteroids, autoimmune diseases treated with corticosteroids or immunosuppressive drugs, and *either inherent genetic diseases or acquired conditions* leading to immunodeficiency were excluded from the study.

Upon suspicion of IFI, the diagnostic works up, including imaging (e.g. computed tomography (CT) scans), blood cultures, pharyngeal swab, serological tests for IFI, skin, nasal or sinus biopsy, and bronchoalveolar lavage for mycological assay were considered according to the site of involvement. The consensus criteria proposed by the EORTC/MSG were used to define IFI. Nonetheless, analysis was restricted to IFI classified as *proven* or *probable*; those with possible IFI were not considered in our investigation¹⁴. Regarding the identification of fungal isolates, morphological features were applied. The demographic and clinical data were recorded from the hospital information registration system using a

questionnaire. Survival at 90 days post-diagnosis was considered.

Data analysis

Statistical analysis was conducted using SPSS software version 24 (Statistical Package for the Social Sciences, Chicago, IL). Frequency Tables, Chi-square, and independent t-tests were employed for quantitative variables, while Fisher and Chi-square tests were utilized for qualitative variables. A significance level of less than 5% ($p < 0.05$) was considered statistically significant.

Ethical statement

Ethical approval for this study was obtained from the Ethics Committee of Tehran University of Medical Sciences on December 6, 2017 (IR.TUMS.MEDICINE.REC.398.738).

RESULTS

During the study period, a total of 1109 patients with HM were admitted to the hematology wards and 67 (6.04%) IFI cases were documented. Molds caused the majority of cases being detected in 66/67 (98.5%) cases, while only one yeast infection was detected (1.5%). Aspergillosis was the most common IFI (57/67, 85.01%). It accounted for 86.4% of mold infections analyzed, followed by mucormycosis (7/67, 10.6%), fusariosis (2/67, 3%) and candidiasis (1/67, 1.5%).

The diagnosis of aspergillosis was categorized as probable in 35/57 cases (61.4%) and proven in the remainder (22 cases, 38.6%). Eighty percent (33/40) of *Aspergillus* cases with positive culture were identified to the species complex level, and *A. section flavi* was the main pathogen (30/33, 90%).

Forty-five cases (67.2%) occurred in male patients and 22 (32.8%) in female. The mean age of patients was 43.16 ± 13.8 years, ranging from 17 to 72 years. No significant correlation was found between the type of IFI and age or gender.

The most common type of malignancy was AML, with most patients undergoing induction chemotherapy and experiencing a mean duration of neutropenia of 11 days. However, the type of IFI did not significantly correlate with the malignancy characteristics of patients.

Lung imaging revealed fungal infection-associated lesions in 52/67 cases (77.6%), primarily with multiple nodules (64.2%). Sinus imaging also demonstrated fungal infection lesions in 46 cases (68.6%), with mostly showing multiple mucosal thickening. The predominant drug treatments were amphotericin B and voriconazole. Surgical interventions, specifically debridement of necrotic lesions, were performed in 15 cases (22.4%), with 10 performed for aspergillosis and five for mucormycosis management. However, there was no significant association between IFI and lung or sinus involvement.

The overall fatality rate of IFI's was 3.5% (42/1190), and the IFI-attributable mortality rate (AMR) was 62.6% (42/67). The AMR was highest for cases with mucormycosis (71.4%) and it was 61.4% for aspergillosis. Notably, the type of fungus and malignancy did not exhibit a significant relationship with patient outcomes. Demographic data and patient characteristics are summarized in Table 1.

The most common underlying condition identified were central venous catheter (CVC) use, mucositis and antibiotic use. Two patients had no underlying condition other than HM, four had only one risk factor, one patient had 2 risk factors, and 60 patients had three to six risk factors (Table 2).

Table 1: Demographic data and patient characteristics

Variable		Aspergillus N (%)	Mucormycosis N (%)	Other N (%)
Gender	Man	39 (68.4%)	3 (42.9%)	3(100%)
	Female	18 (31.6%)	4(57.1%)	0
Age	<21	3 (5.3%)	0	1(33.3%)
	>21	54 (94.7%)	7 (100%)	2 (66.6%)
	Mean	42.6	51	35
	SD	14.04	7.2	16.7
Malignancy	AML	39 (64.8%)	5 (71.4%)	3(100%)
	ALL	9 (15.8%)	1 (14.3%)	0
	CLL	3 (5.3%)	0	0
	Others	6 (10.5%)	1 (14.3%)	0
Treatment stage	No chemotherapy	4 (7%)	3 (42.9%)	1 (33.3%)
	Induction	34 (59.6%)	3 (42.9%)	1 (33.3%)
	Consolidation	11 (19.3%)	1 (14.3%)	1 (33.3%)
	Salvage	7 (12.3%)	0	0
	Maintenance	1 (1.8%)	0	0
Duration of Less than 10 (days)	Does not have neutropenia	4 (7.1%)	4 (57.1%)	1(33.3%)
	>10	29 (50.9%)	1 (14.3%)	2(66.7%)
		24 (40%)	2 (28.6%)	0
Lung imaging	Normal	9(15.8%)	4 (57.1%)	2 (66.7%)
	Nodule	41 (70.2%)	2 (28.6%)	1 (33.3%)
	Consolidation	5 (8.8%)	1 (14.3%)	0
	Ground glass	3 (5.3%)	0	0
Sinus imaging	Normal	19 (33.3%)	1(14.3%)	1(33.3%)
	Single mucosal thickening	7 (12.3%)	3 (42.9%)	1(33.3%)
	Multiple mucosal thickening	31 (54.4%)	3 (42.9%)	1(33.3%)
Simultaneous lung and sinus involvement	No	28 (49.1%)	4(57.1%)	2(66.7%)
	Yes	29 (50.9%)	3(42.9%)	1(33.3%)
Galactomannan	Positive in serum	19 (33.4%)	-	-
	Positive in BAL	2 (3%)	-	-
Type of primary Medication	Caspofungin	4 (7%)	1(14.3%)	1(33.3%)
	Amphotericin deoxycolate	16(28.1%)	2(28.6%)	0
	Amphotericin Liposomal	12 (21.1%)	3(42.9%)	2(66.7%)
	Voriconazole	25 (43.9%)	1(14.3%)	0
Type of treatment changed	Did not change	25 (43.9%)	4(57.1%)	1(33.3%)
	Caspofungin	2 (3.5%)	0	0
	Amphotericin deoxycolate	1(1.8%)	1(14.3%)	0
	Amphotericin Liposomal	3 (5.3%)	1(14.3%)	0
	posaconazole	0	1(14.3%)	0
	Voriconazole	26 (45.6%)	0	2(66.7%)
Surgical Treatment	No	47(82.5%)	2(28.6%)	3(100%)
	Yes	10 (17.5%)	5(71.4%)	0
Outcome	Death	35(61.4%)	5(71.4%)	2(66.7%)
	Recovery	22(38.6%)	2(28.6%)	1(33.3%)

Table 2: Distribution of risk factors for fungal infections in patients with blood malignancy and invasive fungal infections admitted to the blood ward of Shariati Hospital

Risk factors	N	%
Central venous catheter	57	85.1
Mucositis	56	83.6
Taking antibiotics	41	61.2
Previous antifungal prophylaxis	60	89.6
Recent surgery	6	9
Environmental factors (construction around the house)	5	7.5
History of fungal infection	4	6
COPD	3	4.5
DM	2	3
IDU	1	1.5
Previous CMV infection	0	0

DISCUSSION

In recent years, numerous studies have focused on identifying the incidence, risk or prognostic factors for IFI particularly in COVID-19 and transplanted populations. However, the real incidence of these infections in patients with HMs before transplantation has been less appreciated. Revealing the institutional epidemiology of IFIs (incidence rate and predominant etiology) in hematology settings is needed before for implementing antifungal prophylaxis¹⁵.

This study aimed to assess the rate of IFIs, identify the associated risk factors, and explore their consequences in hospitalized patients with HMs over a six-month period. The reported incidence of proven/probable IFI in the different subsets of patients varied from 0.5% among patients with multiple myeloma to 12% in those with AML in series that included both adults and children^{12,15}. A similar incidence of (6%) IFIs was documented in our study. Our data corroborate that molds are responsible for the majority of IFI's, with aspergillosis being observed as the most frequent complication in patients with HMs. Notably, similar findings were reported in studies conducted by Kurosawa et al. and

Pagano et al. in Japan and Italy, emphasizing aspergillosis as the most common IFIs in patients with malignancies^{12,15}. However, unlike these previous studies which reports *A. fumigatus* as the most frequently isolated species^{12,15}, we demonstrated that *A. flavus* was the most prevailing agent causing aspergillosis in Iran.

Several reports have assessed the incidence of candidemia, particularly in critical care settings. Conversely there are far fewer studies on the rate of candidemia in hematology settings. Our data show that yeast infections are less frequent than mold infections in the setting where an anti-yeast agent (e.g. fluconazole) is widely used as antifungal prophylaxis. However, *Candida spp.* are still the predominant yeast pathogens. In contrast, studies by Lin et al.¹⁶ and León-Borrás et al.¹⁷ demonstrated a higher prevalence of IC, particularly in children with malignancy. Specifically, in the study of León-Borrás et al. in Spain invasive *Candida* infections predominated. In addition, Fracchiolla et al. identified IC and IA as the most common IFI's¹⁸. In our study, the increased prevalence of aspergillosis could be attributed to the induction phase of

chemotherapy in individuals with AML. Mucormycosis was the second most common IFI, with a reduced risk due to early administration of amphotericin B known for its effectiveness in preventing and treating mucormycosis^{19, 20}. Given the aggressiveness and high fatality of mucormycosis, the detection of mucormycosis is presumptively underestimated because in majority of cases death occurred before employing diagnostic procedures, including chest and sinus CT scans. Overall, various studies have recently revealed the apparent increases in the rate of mucormycosis, particularly among those who had received voriconazole for antifungal prophylaxis or treatment. Most cases of mucormycosis identified in the pre-chemotherapy phase indicate an immunodeficiency due to a decrease in leukocytes, especially neutrophils, which predisposes patients to fungal infections and subsequent invasion of the arteries, especially the sinuses. An interesting finding of this study was the observation of two cases of *Fusarium* infection, a relatively rare fungus. In a 10-year study from 2000 in Boston Hospital, only 26 cases of fusariosis were observed²¹. In our population the incidence of both mucormycosis and fusariosis remained low.

Despite the majority of patients having CVC, a known risk factor for candidiasis, candidiasis was observed in only one case. Possible explanations include antifungal prophylaxis, such as fluconazole, prescribed to most hospitalized patients with HM in our institution, reducing the risk of IC^{22, 23}. It should be noted that we did not include cases with *Candida* colonization in our assay. Moreover, the method of detection of *Candida* infection in our study was blood culture which has a low positivity rate, so the detection rate of this fungus is probably underestimated. Serological tests which have higher sensitivity than culture based methods such as β -d-Glucan and *Candida* Mannan were not used in our study.

The gender distribution showed no relationship with the type of IFI, and age did not significantly correlate with the fungal infection type. In the study of Fracchiolla et al., the mean age of patients was higher, and there was no significant relationship with the type of fungus¹⁸. AML was the most common

malignancy, consistent with findings by Sheikh Baha'i et al. and Mishra et al.¹³ who showed that AML was the most frequent risk factor for IFIs²⁴. Another study in Japan also reported AML as the most common type of malignancy complicated by IFIs¹². Recently, the list of those patients with manifold risk for IFI development has been elongated as several studies reported that purine analogs usage, use of monoclonal antibodies, rituximab or alemtuzumab which prolongs immunosuppression extend the risk of IFI to other patients (e.g. those with CLL) even in the absence of neutropenia or steroid therapy¹⁵. Moreover, imaging results revealed multiple nodules associated with fungal infections in the lungs, and mucosal thickening in the sinuses. Roughly, half of the cases showed concomitant lung and sinus involvement. In the study of Korula et al., lung involvement was presented in most cases, but sinus involvement was reported in only one-tenth of cases, and only in 2 out of 76 cases, simultaneous lung-sinus involvement occurred²⁵.

Amphotericin B and voriconazole were the predominant antifungal treatments, with debridement of necrotic lesions performed in one-fifth of cases, mostly related to aspergillosis and mucormycosis. In the study of Fracchiolla et al., the antifungal most often used was amphotericin B¹⁸. Mortality rates were nearly identical across different fungal types, and no significant association was found between the type of fungus and patient outcomes. Similarly, the type of malignancy did not significantly impact patient outcomes, with death occurring in over half of AML cases. In the study of Kurosawa et al., mortality was not associated with the type of fungal infection¹². In another study in Taiwan, the highest mortality rate was observed in patients with aspergillosis¹⁶.

Despite the known association between previous cytomegalovirus infection and increased risk of IFIs in individuals with compromised immune systems²⁶ and HMs^{27, 28}, none of the subjects in our study had a history of this infection. The study's limitations include potential inaccuracies in information recording, incomplete or distorted data in some files, a relatively small sample size, and limited access to some patients residing in remote cities.

CONCLUSION

This study revealed that widespread use of anti-yeast prophylaxis has led to significant reduction in candidiasis. However, the predominant fungal infection among patients hospitalized in hematology wards was aspergillosis. AML stands as the most common malignancy for IFIs, often associated with lung and sinus involvement. Despite the high rate of mortality, the study found no significant correlation between the type of IFI and mortality. To gain a more comprehensive understanding, multicenter survey on the prevalence of invasive fungal infections and patterns of antifungal drug resistance across different medical centers is recommended. Additionally, longitudinal studies conducted at longer intervals and the use of specific blood culture methods for *Candida* diagnosis would enhance the depth of insights in subsequent research.

ACKNOWLEDGEMENTS

We deeply appreciate the efforts by Hematology-Oncology and Stem Cell Research Center for their help with providing facilities for this study.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

Funding

Tehran University of Medical Sciences financially supported this work.

REFERENCES

1. Auberger J, Lass-Flörl C, Ulmer H, et al. Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. *International journal of hematology*. 2008; 88:508-15.
2. Hagberg KW, Li L, Peng M, et al. Rates of cancers and opportunistic infections in patients with psoriatic arthritis compared with patients without psoriatic arthritis. *J Clin Rheumatol*. 2016;22(5):241-7.
3. Hachem R, Hanna H, Kontoyiannis D, et al. The changing epidemiology of invasive candidiasis: *Candida glabrata* and *Candida krusei* as the leading causes of candidemia in hematologic malignancy. *Cancer*. 2008;112(11):2493-9.
4. Colombo A, de Almeida Júnior J, Slavin MA, et al. *Candida* and invasive mould diseases in non-neutropenic

critically ill patients and patients with haematological cancer. *Lancet Infect Dis*. 2017;17(11):e344-e356.

5. Ramos ER, Jiang Y, Hachem R, et al. Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles. *Oncologist*. 2011;16(7):1049-60.
6. Nguyen MH, Leather H, Clancy CJ, et al. Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients. *Biol Blood Marrow Transplant*. 2011;17(7):1043-50.
7. Akhrass FA, Debiane L, Abdallah L, et al. Palatal mucormycosis in patients with hematologic malignancy and stem cell transplantation. *Med Mycol*. 2011;49(4):400-5.
8. Hammond SP, Baden LR, Marty FM. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. *Antimicrob Agents Chemother*. 2011;55(11):5018-21.
9. Herbrecht R, Bories P, Moulin JC, et al. Risk stratification for invasive aspergillosis in immunocompromised patients. *Ann N Y Acad Sci*. 2012;1272:23-30
10. Mühlemann K, Wenger C, Zenhäusern R, et al. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. *Leukemia*. 2005;19(4):545-50.
11. Badiie P, Hadadi P, Zareifar S, et al. Prevalence of fungal infections in children with hematologic disorders and determination of anti-fungal susceptibility in isolated species. *J Kerman Univ. Medical Sci*. 2015;22(4):410-23.
12. Kurosawa M, Yonezumi M, Hashino S, et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. *Int J Hematol*. 2012;96(6):748-57.
13. Sheikhbahaei S, Mohammadi A, Sherkat R, et al. Invasive fungal infection in febrile patients with hematologic malignancies undergoing chemotherapy in Iran. *Endocr Metab Immune Disord Drug Targets*. 2019;19(3):302-307.
14. Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clin Infect Dis*. 2020;71(6):1367-1376.
15. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. *Haematologica*. 2006;91(8):1068-75.
16. Lin GL, Chang HH, Lu CY, et al. Clinical characteristics and outcome of invasive fungal infections in pediatric

- acute myeloid leukemia patients in a medical center in Taiwan. *J Microbiol Immunol Infect.* 2018;51(2):251-259.
17. de León-Borrás R, DelPilar-Morales E, Rivera-Pérez N, et al. Factors associated to invasive fungal infection in hispanic patients with hematological malignancies. *Bol Asoc Med P R.* 2017;109(1):43-48.
18. Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections. *Clin Epidemiol.* 2011;3:175-91.
19. Lewis RE, Albert ND, Liao G, et al. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. *Antimicrob Agents Chemother.* 2010;54(3):1298-304.
20. Kazak E, Aslan E, Akalin H, et al. A mucormycosis case treated with a combination of caspofungin and amphotericin B. *J Mycol Med.* 2013;23(3):179-84.
21. Muhammed M, Anagnostou T, Desalermos A, et al. Fusarium infection: report of 26 cases and review of 97 cases from the literature. *Medicine (Baltimore).* 2013;92(6):305-316.
22. Lortholary O, Desnos-Ollivier M, Sitbon K, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. *Antimicrob Agents Chemother.* 2011;55(2):532-8.
23. Ha JF, Italiano CM, Heath CH, et al. Candidemia and invasive candidiasis: a review of the literature for the burns surgeon. *Burns.* 2011;37(2):181-95.
24. Mishra P, Agrawal N, Bhurani D, et al. Invasive Fungal Infections in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy. *Indian J Hematol Blood Transfus.* 2020;36(1):64-70.
25. Korula A, Abraham A, Abubacker FN, et al. Invasive fungal infection following chemotherapy for acute myeloid leukaemia—experience from a developing country. *Mycoses.* 2017;60(10):686-91.
26. Yong MK, Slavin MA, Kontoyiannis DP. Invasive fungal disease and cytomegalovirus infection: is there an association? *Curr Opin Infect Dis.* 2018;31(6):481-489.
27. Marchesi F, Pimpinelli F, Ensoli F, et al. Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant. *Hematol Oncol.* 2018;36(2):381-391.
28. Xuan L, Huang F, Fan Z, et al. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. *J Hematol Oncol.* 2012; 2:5:46.